OncoMatch/Clinical Trials/NCT06755684
Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
Is NCT06755684 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Befotertinib combined Bevacizumab and Befotertinib combined platinum-based double chemotherapy for egfr.
Treatment: Befotertinib combined Bevacizumab · Befotertinib combined platinum-based double chemotherapy — This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitive mutation
Disease stage
Required: Stage II, IIIA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic anti-cancer treatment
The patient has undergone any systemic anti-cancer treatment for NSCLC, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment, etc.
Lab requirements
Blood counts
Other major organs shall function well (liver, kidney, blood system, etc.)
Kidney function
Other major organs shall function well (liver, kidney, blood system, etc.)
Liver function
Other major organs shall function well (liver, kidney, blood system, etc.)
Other major organs shall function well (liver, kidney, blood system, etc.)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify